In pancreatic resection patients, mean cost was lower with pasireotide than placebo, without statistical significance (MP$22,800 versus MP$23,900, P = 0.571).
In plain wordsIn pancreatic resection patients, mean cost was lower with pasireotide than placebo, but the difference was not statistically significant.
- Peptide
- Pasireotide
- Outcome
- DecreaseTotal direct cost
- Study
n = 300
- Comparator
- Placebo
- Outcome group
- Cost-effectiveness · Whole body
- Studied dose
- Dose not stated
Measurements
- Mean total cost
- 22,800 MP$
- pasireotide
- Mean total cost
- 23,900 MP$
- placebo
- P value
- 0.571
- pasireotide versus placebo
Source sentences
The mean cost was lower in the pasireotide (n = 152) group than the placebo (n = 148) group; however, this did not reach statistical significance (pasireotide, MP$22,800 vs placebo, MP$23,900: P = 0.571).
2 context sentences(design, population, supporting numbers)
An institutional modeling system was utilized to obtain total direct cost estimates from the 300 patients included in the trial.
Total direct costs were calculated from the index admission to 90 days after resection.